Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
ASBP stock price ended at $1.81 on 木曜日, after dropping 5.24%
On the latest trading day Jan 22, 2026, the stock price of ASBP fell by 5.24%, dropping from $2.01 to $1.81. During the session, the stock saw a volatility of 18.13%, with prices oscillating between a daily low of $1.71 and a high of $2.02. On the latest trading day, the trading volume for ASBP rose by 1.2M shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 1.5M shares were traded, with a market value of approximately $194.5M.